Business Context and Reporting Period
Company: Decoy Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2026
Event: Entry into a Material Definitive Agreement for a private placement of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Securities Issued: 592,217 shares of Common Stock (or Pre-Funded Warrants) plus Milestone Warrants (Series A, B, and C).
- Purchase Price: $5.91 per share.
- Expected Gross Proceeds: Approximately $3.5 million (excluding placement fees and warrant exercise proceeds).
- Potential Additional Proceeds: Up to approximately $17.5 million if all Milestone Warrants are exercised in full.
- Placement Agent Fees: 9.0% of gross proceeds plus expense reimbursement up to $100,000 total.
- Use of Proceeds: General corporate purposes, specifically to advance the lead asset into clinical trials.
Material Changes and Transaction Structure
The filing announces a significant change in capital structure through a private placement with an institutional/accredited investor. Key structural elements include:
- Warrant Structure:
- Series A Warrants: 100% of shares purchased; exercisable upon filing a Clinical Trial Application for a Phase 1 trial in the EEA.
- Series B Warrants: 200% of shares purchased; exercisable upon receipt of UK MHRA approval for a Phase 2a human challenge trial.
- Series C Warrants: 200% of shares purchased; exercisable upon public announcement that the Phase 2a trial met its primary endpoint.
- Stockholder Approval: Milestone Warrants are not exercisable until stockholder approval is obtained. The Company must hold a special meeting within 90 days of closing to seek this approval.
- Lock-Up Agreements: Executive officers and directors are restricted from selling shares for 90 days following the closing date.
- Registration Rights: The Company must file a registration statement for resale of securities within 15 days, with effectiveness required within 45 to 90 days depending on SEC review status.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The Company intends to utilize the net proceeds to advance its lead asset into clinical trials. The transaction is contingent on customary closing conditions and the satisfaction of regulatory milestones for warrant exercise.
Risks and Contingencies:
- Closing Risk: The transaction is subject to satisfaction of closing conditions.
- Approval Risk: Milestone Warrants cannot be exercised without stockholder approval, which is not guaranteed.
- Milestone Risk: Additional proceeds depend on achieving specific clinical and regulatory milestones (Phase 1 filing, Phase 2a approval, and Phase 2a primary endpoint success).
- Dilution: The issuance of shares and warrants, particularly the 500% aggregate warrant coverage (100% + 200% + 200%), represents significant potential dilution.
- Forward-Looking Statements: Actual results may differ materially due to risks described in the Company's 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received (expected ~$3.5 million).
- Confirm the date of the special stockholder meeting to approve Milestone Warrant exercise.
- Monitor the Company's progress toward the specific clinical milestones required to trigger warrant exercisability (Phase 1 filing, UK Phase 2a approval, Phase 2a endpoint).
- Review the effective date of the resale registration statement to determine when the new shares can be freely traded.
- Assess the impact of the 9.0% placement fee and potential liquidated damages (up to 10.5% of subscription amount) on net cash flow.